Evidence map›Paper›PMID 21138881›Full record

ReviewChest2010

Recent advances in testing for latent TB.

Neil W Schluger, Joseph Burzynski

Open access · bronzeAbstract readComparative StudyReview
In one paragraph

Review in Chest, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Article
  3. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022
    Article
  4. Observational
  5. Tuberculosis: Past, present and future of the treatment and drug discovery research.Current research in pharmacology and drug discovery · 2021
    Review
  6. Observational
  7. Article
  8. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019
    Article
  9. Low Prevalence of Tuberculin Skin Test Boosting among Community Residents in Uganda.The American journal of tropical medicine and hygiene · 2018
    Article
  10. Asian spine journal · 2017
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Neil W SchlugerDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, NY 10032, USA. ns311@columbia.edu
Joseph Burzynski
Columbia University Irving Medical Center · USNew York City Department of Health and Mental Hygiene · US

Funding

Mentoring in Tuberculosis Patient-Oriented ResearchK24HL004074 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHLUGER, NEIL W. · 1999 to 2009
$1.2M
NHLBI NIH HHS K24 HL004074
6 · The paper itself

Abstract

After more than a century of relying on skin testing for the diagnosis of latent TB infection, clinicians now have access to blood-based diagnostics in the form of interferon γ release assays (IGRAs). These tests are generally associated with higher sensitivity and specificity for diagnosis of latent TB infection. This article reviews the indications for testing and treatment of latent TB infection in the overall context of a TB control program and describes how IGRAs might be used in specific clinical settings and populations, including people having close contact with an active case of TB, the foreign born, and health-care workers.

Indexed as

Antigens, BacterialFemaleForecastingHumansImmunologic TestsInterferon-gammaLatent TuberculosisMaleSensitivity and SpecificityTuberculin TestUnited StatesAntigens, BacterialInterferon-gamma

Identifiers

PMID21138881
PMCPMC2998209
OpenAlexW2024325151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.